Literature DB >> 6603247

Transabdominal oesophageal transection for oesophageal varices: experience in 101 patients.

K Umeyama, K Yoshikawa, T Yamashita, T Todo, K Satake.   

Abstract

The results of transabdominal oesophageal transection in 101 patients with oesophageal varices are reported. The primary diagnosis was liver cirrhosis and 65 patients, idiopathic portal hypertension in 29 and extrahepatic portal obstruction in 7. Twelve patients died postoperatively. The mortality rate for emergency operations was higher than that for elective and prophylactic procedures. The majority of patients died from hepatic failure. Improvement, judged by radiographic and endoscopic examination, was 100 per cent and 96 per cent, respectively. Post-transection rebleeding was observed in 14 of 89 patients during the follow-up period of 1-13 years. There were 25 late deaths, caused mainly by hepatic failure. The 5-year survival rate, including postoperative deaths, was 72 per cent in idiopathic portal hypertension and 55 per cent in liver cirrhosis. We suggest that transabdominal oesophageal transection is an acceptable operative procedure for oesophageal varices.

Entities:  

Mesh:

Year:  1983        PMID: 6603247     DOI: 10.1002/bjs.1800700710

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Effect of spontaneous portosystemic shunts on hemorrhage from esophagogastric varices.

Authors:  Jan-Sing Hsieh; Jaw-Yuan Wang; Che-Jen Huang; Fang-Ming Chen; Tsung-Jen Huang
Journal:  World J Surg       Date:  2003-12-05       Impact factor: 3.352

2.  Portographic evaluation for recurrent esophagogastric varices following devascularization surgery.

Authors:  J S Hsieh; C J Huang; J Y Wang; T J Huang
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Jan-Feb       Impact factor: 2.740

3.  Sugiura procedure for management of variceal bleeding in Japan.

Authors:  Y Idezuki; N Kokudo; K Sanjo; Y Bandai
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.